Drug Trial Radar · NCT01869556
Comparison of IV Ergonovine With IM Carboprost, With Oxytocin IV, During Cesarean Section for Failure to Progress
Last checked: Nov 20, 2026Latest source record: Sep 24, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
105
Actual
Start
Jun 4, 2013
Primary completion
Jul 8, 2019
Study completion Sep 30, 2019
Sponsor
- Lead sponsor
- Samuel Lunenfeld Research Institute, Mount Sinai HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 5, 2013
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- Female only, from 14 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Patients having Cesarean section after they have been in labor for many hours bleed much more, in average twice as much, as compared with patients having an elective Cesarean section. The investigators believe a simple change in practice might contribute to reduce this bleeding. This study will involve the use of oxytocin (also known as syntocinon), ergonovine (also known as ergot) and carboprost (also known as hemabate). Oxytocin is routinely used to help contract the uterus and keep it contracted after the delivery of the baby and placenta, so as to reduce the amount of blood loss. Ergonovine is also given through the intravenous line, while carboprost is given as an injection in the muscle. Although they are not routinely given in every case, these are very frequently given as rescue medications to patients who fail to respond appropriately to oxytocin. This study is designed to determine if ergonovine or carboprost given in association with oxytocin, in a preventive way, after delivery of the baby and placenta, can reduce the amount of blood loss during Cesarean sections following a trial of labour.
Conditions
- Postpartum Hemorrhage
Interventions
OxytocinDrug
Oxytocin 5IU IV bolus, followed by an infusion of oxytocin 20IU/L, running at at rate of 40mIU/min for 8 hours
ErgotDrug
Ergot 0.25mg IV
CarboprostDrug
Carboprost 0.25mg IM
Primary outcomes
What the sponsor says the trial is designed to measure.
- Need for additional uterotonics intraoperativelyTime frame: 1 hour
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Mount Sinai Hospital
Toronto, Ontario, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.